Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehaf070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review.
Clin Genitourin Cancer
February 2025
Department of Urology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address:
Introduction: Treatment patterns for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC) are inconsistently reported. We retrospectively described demographic, clinical, and treatment characteristics for these patients and assessed their clinical outcomes.
Patients And Methods: Medical charts of patients with BCG-unresponsive high-risk NMIBC (carcinoma in situ [cohort A] or T1/high-grade Ta [cohort B]) who were ineligible for or declined RC documented between January 1, 2011, and December 31, 2018, at 15 academic centers were reviewed.
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months.
Eur Heart J
March 2025
Cardiovascular Science Department, Fondazione Policlinico Universitario Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy.
Efficient coding in biophysically realistic excitatory-inhibitory spiking networks.
Elife
March 2025
Institute of Neural Information Processing, Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
The principle of efficient coding posits that sensory cortical networks are designed to encode maximal sensory information with minimal metabolic cost. Despite the major influence of efficient coding in neuroscience, it has remained unclear whether fundamental empirical properties of neural network activity can be explained solely based on this normative principle. Here, we derive the structural, coding, and biophysical properties of excitatory-inhibitory recurrent networks of spiking neurons that emerge directly from imposing that the network minimizes an instantaneous loss function and a time-averaged performance measure enacting efficient coding.
View Article and Find Full Text PDFHealthcare metaverse in surgery: scoping review.
BJS Open
March 2025
Department of Colorectal Surgery, Manchester University NHS Foundation Trust, Manchester, UK.
Background: The metaverse is an emerging concept in surgery, with much interest in its highly immersive and interactive virtual environment. Despite the growing interest and importance in healthcare, the metaverse is still very much in its early phase of evolution and adoption in surgery, with debate on its definition and components. This scoping review provides a summary of the evidence and current understanding for the use of the metaverse in surgery.
View Article and Find Full Text PDFPembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Nat Med
March 2025
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors. In the phase 3 NRG GY018 study, pembrolizumab plus chemotherapy significantly improved investigator-assessed progression-free survival (PFS; primary endpoint) versus placebo plus chemotherapy in patients with advanced/metastatic/recurrent endometrial cancer regardless of mismatch repair status.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!